Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray

Inclusion criteria: * Females (ages 6 to 11) who have not begun menses. * Males (ages 6 to 12). * Tanner Stage 1. * History of SAR (Seasonal Allergic Rhinitis) or PAR (Perennial Allergic Rhinitis) of at least one year with either a current level of allergic rhinitis symptoms that warrants treatment and/or expected symptoms during a majority of the study period. * Positive skin test to an appropriate seasonal or perennial allergen. Exclusion criteria: * History of abnormal growth or gross malnutrition. * Clinically significant laboratory abnormality. * History of any condition that may have substantially affected growth. * Historical or current evidence of clinically significant, uncontrolled disease of any body system. * Any asthma other than mild, intermittent asthma controlled by short-acting, beta-agonists. * Recent major surgery and/or trauma to the legs. * History of adrenal insufficiency. * Current or prior treatment with any medication that may have a potential for an ongoing effect on linear growth. * Use of corticosteroids, by any route, within 4 weeks prior to Visit 1. * Any nasal condition or deformity that would impair nasal breathing or deposition of medication. * Physical impairment that would affect the subject's ability to participate in the study.